180 related articles for article (PubMed ID: 26939707)
1. Novel Anti-CRR9/CLPTM1L Antibodies with Antitumorigenic Activity Inhibit Cell Surface Accumulation, PI3K Interaction, and Survival Signaling.
Puskás LG; Mán I; Szebeni G; Tiszlavicz L; Tsai S; James MA
Mol Cancer Ther; 2016 May; 15(5):985-97. PubMed ID: 26939707
[TBL] [Abstract][Full Text] [Related]
2. CLPTM1L/CRR9 ectodomain interaction with GRP78 at the cell surface signals for survival and chemoresistance upon ER stress in pancreatic adenocarcinoma cells.
Clarke WR; Amundadottir L; James MA
Int J Cancer; 2019 Mar; 144(6):1367-1378. PubMed ID: 30468251
[TBL] [Abstract][Full Text] [Related]
3. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
[TBL] [Abstract][Full Text] [Related]
4. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
5. CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis.
James MA; Vikis HG; Tate E; Rymaszewski AL; You M
Cancer Res; 2014 Feb; 74(4):1116-27. PubMed ID: 24366883
[TBL] [Abstract][Full Text] [Related]
6. Targeted biologic inhibition of both tumor cell-intrinsic and intercellular CLPTM1L/CRR9-mediated chemotherapeutic drug resistance.
Parashar D; Geethadevi A; McAllister D; Ebben J; Peterson FC; Jensen DR; Bishop E; Pradeep S; Volkman BF; Dwinell MB; Chaluvally-Raghavan P; James MA
NPJ Precis Oncol; 2021 Mar; 5(1):16. PubMed ID: 33654182
[TBL] [Abstract][Full Text] [Related]
7. Nephrin, a transmembrane protein, is involved in pancreatic beta-cell survival signaling.
Kapodistria K; Tsilibary EP; Politis P; Moustardas P; Charonis A; Kitsiou P
Mol Cell Endocrinol; 2015 Jan; 400():112-28. PubMed ID: 25448064
[TBL] [Abstract][Full Text] [Related]
8. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus.
James MA; Wen W; Wang Y; Byers LA; Heymach JV; Coombes KR; Girard L; Minna J; You M
PLoS One; 2012; 7(6):e36116. PubMed ID: 22675468
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Ca
Liu Z; Zhang S; Hou F; Zhang C; Gao J; Wang K
Int J Cancer; 2019 May; 144(9):2215-2226. PubMed ID: 30243029
[TBL] [Abstract][Full Text] [Related]
10. Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer.
Totiger TM; Srinivasan S; Jala VR; Lamichhane P; Dosch AR; Gaidarski AA; Joshi C; Rangappa S; Castellanos J; Vemula PK; Chen X; Kwon D; Kashikar N; VanSaun M; Merchant NB; Nagathihalli NS
Mol Cancer Ther; 2019 Feb; 18(2):301-311. PubMed ID: 30404927
[TBL] [Abstract][Full Text] [Related]
11. 2-Arylthiazolidine-4-carboxylic acid amides (ATCAA) target dual pathways in cancer cells: 5'-AMP-activated protein kinase (AMPK)/mTOR and PI3K/Akt/mTOR pathways.
Li CM; Narayanan R; Lu Y; Hurh E; Coss CC; Barrett CM; Miller DD; Dalton JT
Int J Oncol; 2010 Oct; 37(4):1023-30. PubMed ID: 20811725
[TBL] [Abstract][Full Text] [Related]
12. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of miR-494 Inhibits Cell Growth and Invasion and Induces Cell Apoptosis by Targeting Cleft Lip and Palate Transmembrane 1-Like in Esophageal Squamous Cell Carcinoma.
Zhang R; Chen X; Zhang S; Zhang X; Li T; Liu Z; Wang J; Zang W; Wang Y; Du Y; Zhao G
Dig Dis Sci; 2015 May; 60(5):1247-55. PubMed ID: 25480402
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
[TBL] [Abstract][Full Text] [Related]
15. Novel Anti-TM4SF1 Antibody-Drug Conjugates with Activity against Tumor Cells and Tumor Vasculature.
Visintin A; Knowlton K; Tyminski E; Lin CI; Zheng X; Marquette K; Jain S; Tchistiakova L; Li D; O'Donnell CJ; Maderna A; Cao X; Dunn R; Snyder WB; Abraham AK; Leal M; Shetty S; Barry A; Zawel L; Coyle AJ; Dvorak HF; Jaminet SC
Mol Cancer Ther; 2015 Aug; 14(8):1868-76. PubMed ID: 26089370
[TBL] [Abstract][Full Text] [Related]
16. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
Talbert EE; Yang J; Mace TA; Farren MR; Farris AB; Young GS; Elnaggar O; Che Z; Timmers CD; Rajasekera P; Maskarinec JM; Bloomston M; Bekaii-Saab T; Guttridge DC; Lesinski GB
Mol Cancer Ther; 2017 Feb; 16(2):344-356. PubMed ID: 27811010
[TBL] [Abstract][Full Text] [Related]
17. In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models.
Hughes PE; Rex K; Caenepeel S; Yang Y; Zhang Y; Broome MA; Kha HT; Burgess TL; Amore B; Kaplan-Lefko PJ; Moriguchi J; Werner J; Damore MA; Baker D; Choquette DM; Harmange JC; Radinsky R; Kendall R; Dussault I; Coxon A
Mol Cancer Ther; 2016 Jul; 15(7):1568-79. PubMed ID: 27196782
[TBL] [Abstract][Full Text] [Related]
18. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
[No Abstract] [Full Text] [Related]
19. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Singh AR; Joshi S; Burgoyne AM; Sicklick JK; Ikeda S; Kono Y; Garlich JR; Morales GA; Durden DL
Mol Cancer Ther; 2016 Nov; 15(11):2553-2562. PubMed ID: 27496136
[TBL] [Abstract][Full Text] [Related]
20. CLPTM1L is overexpressed in lung cancer and associated with apoptosis.
Ni Z; Tao K; Chen G; Chen Q; Tang J; Luo X; Yin P; Tang J; Wang X
PLoS One; 2012; 7(12):e52598. PubMed ID: 23300716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
